BioGenerator Ventures

Geneoscopy, LLC is a diagnostic company based in Saint Louis, Missouri, focused on developing non-invasive solutions for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, Geneoscopy utilizes stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel aimed at identifying colorectal cancer by detecting the effects of cancer-related DNA mutations. The company is committed to improving colorectal cancer screening compliance and facilitating early detection, thereby reducing the associated morbidity and mortality. By employing a novel methodology to extract human RNA transcripts from stool samples, Geneoscopy aims to provide a reliable alternative to traditional colonoscopies, which are often viewed as unpleasant and invasive. In addition to its colorectal cancer diagnostic test, Geneoscopy is also exploring other potential applications of its RNA technology for additional gastrointestinal conditions.

Impetus AG is engaged in the development of innovative insect control solutions that prioritize safety, effectiveness, and sustainability. The company specializes in creating bi-specific plant-based proteins designed to protect crops from harmful insects. Utilizing Bacillus thuringiensis technology, Impetus AG's products enhance crop yield by integrating antibodies within plant structures. This approach addresses the challenge of insect resistance that has emerged with existing commercial insect control products, offering farmers durable alternatives that support sustainable agriculture.

SentiAR, Inc. is a digital health and software company based in St. Louis, Missouri, focused on enhancing interventional procedures through its innovative 3D augmented reality platform. Incorporated in 2017 and spun out of Washington University, SentiAR develops a holographic visualization system that transforms CT, MRI, and real-time mapping data into interactive 3D holograms. These holograms provide clinicians with a real-time view of the patient's anatomy and catheter positioning, effectively "floating" above the patient, which aids in the treatment and analysis of cardiac arrhythmias. The platform is designed to be fully controllable in a hands-free manner, promoting ergonomic benefits during complex procedures. SentiAR aims to improve the delivery of care for both clinicians and patients and is working towards FDA submission for its technology.

Omniose, formerly known as VaxNewMo LLC, is a biotechnological company based in St. Louis, Missouri, focused on the development of next-generation conjugate vaccines targeting infectious diseases. Founded in 2016, the company utilizes proprietary in vivo conjugating technology to create innovative vaccine solutions. By advancing its research in conjugate vaccines, Omniose aims to address significant health challenges posed by infectious pathogens, contributing to global public health efforts.

Cadre Bioscience, LLC, founded in 2019 and based in Saint Louis, Missouri, focuses on developing innovative therapeutics for human diseases with significant unmet medical needs. The company is engaged in creating a portfolio of early-stage therapeutic assets, employing a strategic approach to de-risking and facilitating their development. By raising capital and attracting management expertise, Cadre aims to advance its assets toward commercialization, ultimately enhancing market access and improving patient outcomes.

Healthy Bytes, Inc. is a technology company that specializes in personalized nutritional counseling through its innovative platform. Founded in 2014 and headquartered in Saint Louis, Missouri, with an additional office in New York, it connects physicians, employers, and patients to facilitate access to registered dietitians. The platform allows users to schedule private consultations and receive expert guidance tailored to their health needs, particularly for conditions such as obesity, diabetes, high blood pressure, cardiovascular disease, and orthopedic issues. Employees can utilize their existing medical benefits to cover the costs associated with consultations, thereby promoting a healthier workforce through accessible nutritional support.

Readout is a digital health company with a mission to help patients better manage their own health by providing novel, clinically-backed tools to easily measure health biomarkers. Biosense was launched in early 2020 as a Class 1 medical device in the clinical, consumer, and research market after a successful clinical trial. As the only clinically-backed breath ketone measurement handheld device+app, Biosense provides full-day feedback of ketosis with unlimited measurements leading to protocol adherence and better outcomes. Biosense is used by obesity and diabetes clinics for in-home testing of ketosis, pharma and academic trials, as well as DTC via https://mybiosense.com.

Aggio, LLC is an information technology company that specializes in developing cloud-based sales applications tailored for the agriculture industry. Established in 2016 and headquartered in St. Louis, Missouri, with an additional location in Madison, New Jersey, Aggio offers a platform designed to enhance marketing and sales processes. Its solutions facilitate data-driven decision-making through advanced analytics, data harmonization, and visualization, enabling clients to effectively engage their customers and channel partners.

BacterioScan, Inc. is a medical device company based in St. Louis, Missouri, focused on diagnosing and treating infectious diseases. The company has developed the 216Dx UTI System, which detects bacteria indicative of urinary tract infections (UTIs) in clinical urine samples and helps identify suitable antibiotic treatments. Additionally, BacterioScan offers the 216R Antibiotic Susceptibility Testing System, designed to detect bacterial infections, assess antibiotic resistance, and provide clinicians with tailored antimicrobial resistance profiles. Its precision bench-top systems facilitate rapid detection and real-time quantification of microbial growth, significantly enhancing laboratory efficiency compared to traditional plating methods. This innovative approach not only aids clinicians in personalizing patient care but also supports researchers in accelerating the development of new antibiotics. BacterioScan's technology aims to improve the quality of antibiotic therapy and mitigate the risks associated with antibiotic resistance.

Arch Innotek, LLC is a biotechnology company based in St. Louis, Missouri, that specializes in engineering microorganisms to produce natural ingredients aimed at enhancing human and animal health. Founded in 2013, the company focuses on developing high-value molecules through sustainable fermentation processes, particularly natural carotenoid antioxidants derived from yeast. Arch Innotek's offerings cater to various industries, including food, feed, pharmaceuticals, and cosmetics. In addition to ingredient production, the company provides a range of laboratory services, such as HPLC analysis, LC-MS analysis, protein purification, fermentation strain optimization, and vector construction for protein expression and molecular cloning. Through its innovative technologies, Arch Innotek aims to deliver affordable and sustainable natural nutrition alternatives for consumers.

Start Right specializes in the production of convenient, protein-rich breakfast foods, focusing primarily on waffles. These waffles are designed to support a fit and active lifestyle, containing a blend of egg and dairy proteins, as well as essential fiber, fruits, and vegetables. They are gluten-free and free from added sugars, making them a nutritious option for consumers seeking a healthy breakfast solution. The company's mission is to empower individuals to start their day with a balanced meal that meets their dietary needs.

Impetus AG is engaged in the development of innovative insect control solutions that prioritize safety, effectiveness, and sustainability. The company specializes in creating bi-specific plant-based proteins designed to protect crops from harmful insects. Utilizing Bacillus thuringiensis technology, Impetus AG's products enhance crop yield by integrating antibodies within plant structures. This approach addresses the challenge of insect resistance that has emerged with existing commercial insect control products, offering farmers durable alternatives that support sustainable agriculture.

Kalocyte is a pre-clinical stage healthcare biotech startup company that provides artificial red blood cell substitutes used for trauma care related services. The company develops a demonstrated proof of concept for ErythroMer, a dried, bio-inspired artificial red blood cell envisioned for use when stored red blood cells are unavailable, undesirable, or in short supply. Kalocyte was founded in 2016 and is headquartered in Baltimore, Maryland.

Omniose, formerly known as VaxNewMo LLC, is a biotechnological company based in St. Louis, Missouri, focused on the development of next-generation conjugate vaccines targeting infectious diseases. Founded in 2016, the company utilizes proprietary in vivo conjugating technology to create innovative vaccine solutions. By advancing its research in conjugate vaccines, Omniose aims to address significant health challenges posed by infectious pathogens, contributing to global public health efforts.

Canopy Biosciences is a biotechnology company based in St. Louis, Missouri, founded in 2016. It specializes in providing research tools and services for genetic engineering and personalized medicine. The company's gene editing technology, known as TUNR, works by targeting translation elongation to insert polyA tracks into specific coding regions of the genome. This process effectively reduces the levels of mRNA transcribed from the gene, leading to a suppression of protein expression. The technology was initially developed by Professors Sergej Djuranovic and Rachel Green at Washington University School of Medicine and Johns Hopkins University, respectively. Canopy Biosciences operates as a subsidiary of Bruker Corporation.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

Atomation, founded in Tel Aviv and now with headquarters in Saint Louis, Missouri, is a business-to-business solutions company that uses an innovative Internet of Things (IoT) platform to connect existing, in-field, legacy objects and assets to the internet. Focused on making the data gathered by sensors into useful and actionable information, Atomation solves problems differently with affordable and simple solutions that allow businesses to transform operations and optimize their bottom line.

Plastomics Inc. is a biotechnology company based in Saint Louis, Missouri, that specializes in chloroplast genetic engineering to enhance crop performance. Founded in 2016, the company focuses on developing advanced crops through gene stacking and rapid breeding techniques, aimed at improving yield production and nutritional quality. Plastomics' technology platform allows for the precise insertion of beneficial traits into the chloroplasts of plant cells, which helps seed companies create more effective biotech crops. This innovative approach not only eliminates cross-pollination but also enables unique maternal inheritance, thereby reducing both breeding timelines and costs associated with bringing new products to market. Through its efforts, Plastomics addresses various challenges faced by the agricultural industry.

SentiAR, Inc. is a digital health and software company based in St. Louis, Missouri, focused on enhancing interventional procedures through its innovative 3D augmented reality platform. Incorporated in 2017 and spun out of Washington University, SentiAR develops a holographic visualization system that transforms CT, MRI, and real-time mapping data into interactive 3D holograms. These holograms provide clinicians with a real-time view of the patient's anatomy and catheter positioning, effectively "floating" above the patient, which aids in the treatment and analysis of cardiac arrhythmias. The platform is designed to be fully controllable in a hands-free manner, promoting ergonomic benefits during complex procedures. SentiAR aims to improve the delivery of care for both clinicians and patients and is working towards FDA submission for its technology.

CoverCress is a biotechnology company that focuses on research and development of renewable fuel and livestock feed. It specializes in producing an oilseed crop for food, bioenergy, and cattle feed. It specializes in the fields of agriculture, biotechnology, plants, genetics, cover crop, and precision agriculture. CoverCress was founded in 2013 by Jerry Steiner and Dr. Tim Ulmasov and is headquartered in St. Louis Missouri.

S4 is a technology service company that provides risk management solutions to ensure food production. It also develops index-based coverage to transfer the agriculture industry's volatilities to the financial markets, through OTC-derivatives contracts. The company offers products and services are used by a broad range of customers including large growers, crop protection and seeds suppliers, crop insurance providers, banking, and commodity exchanges. S4 integrates the harvest information with a planting plan, seed density, and soil analysis. They had developed a decision-making geo-referenced platform for the agricultural producer. They seek to improve the decision-making process in complex environments to collaborate in the global challenge of generating quality food for humanity. S4 was founded on 2011 and is headquartered in Buenos Aires, Argentina.

MedAware Solutions, Inc. is a healthcare communication technology company based in St. Louis, Missouri, founded in 2014. The company offers mViva, a comprehensive platform designed to facilitate care coordination among healthcare teams, payers, patients, and their families. This platform provides tools for real-time communication and collaboration throughout the continuum of care, allowing multi-disciplinary teams to engage in patient-centric discussions. It also enables patients and care teams to securely capture and share data in a HIPAA-compliant environment. By optimizing clinical resources and enhancing healthcare outcomes, MedAware Solutions aims to improve the overall patient experience while reducing costs in healthcare delivery.

Accuronix Therapeutics, Inc. develops oncology therapies for pancreatic cancer. The company was founded in 2015 and is based in the United States.

Edison Agrosciences, Inc. is an agricultural biotechnology company based in Durham, North Carolina, established in 2013. The company specializes in developing innovative biotechnological solutions for producing plant-based industrial materials, with a primary emphasis on alternative rubber crops. These crops are intended for use in consumer, medical, and industrial products. Edison Agrosciences is focused on engineering yield improvements and creating novel production methods within suitable plant systems. The company is building an intellectual property portfolio that encompasses various technical strategies and is actively forming strategic partnerships to reduce risks associated with the pilot-scale validation of crops and products. The leadership team at Edison boasts a proven track record of success in the industry.

S4 is a technology service company that provides risk management solutions to ensure food production. It also develops index-based coverage to transfer the agriculture industry's volatilities to the financial markets, through OTC-derivatives contracts. The company offers products and services are used by a broad range of customers including large growers, crop protection and seeds suppliers, crop insurance providers, banking, and commodity exchanges. S4 integrates the harvest information with a planting plan, seed density, and soil analysis. They had developed a decision-making geo-referenced platform for the agricultural producer. They seek to improve the decision-making process in complex environments to collaborate in the global challenge of generating quality food for humanity. S4 was founded on 2011 and is headquartered in Buenos Aires, Argentina.

Nitrogenics is a plant biotechnology company providing research analysis on nitrogen fixation in crop plants. Nitrogenics' services include data related to plant enzymes that are inserted in the genome of tobacco, enabling researchers to get to research on plants that absorbs nitrogen directly from the atmosphere, rather than from fertilized soil.

Antegrin Therapeutics, LLC, is a drug discovery and development company focused on the development of novel therapies for fibrotic diseases. Our lead program aims to develop a treatment for idiopathic pulmonary fibrosis, a progressive, life-threatening condition that currently has no FDA-approved medication.

MedSocket of Missouri, Inc. specializes in health information technology solutions aimed at enhancing patient care efficiency and quality. Founded in 2012 and based in Columbia, Missouri, the company offers two patented products: 1-Click Decision Support (1-CDS) and 1-Search. Designed by clinicians for clinicians, these tools facilitate quick access to evidence-based information at the point of care, thereby improving healthcare decision-making. Both technologies have undergone successful piloting at the University of Missouri Health System, demonstrating their potential to reduce readmission rates, minimize transcription errors, and improve overall patient outcomes. MedSocket was established by Dr. Karl Kochendorfer, who recognized the need for rapid information retrieval in clinical settings, and further developed by Matt Botkin and Jayne Williams, who contributed business and information science expertise to the company’s mission.

Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds from Euclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs.

Cofactor Genomics is a biotechnology company focused on advancing precision medicine through predictive immune modeling. By leveraging its expertise in RNA sequencing and expression analysis, Cofactor aims to move beyond traditional single-analyte biomarkers to develop multidimensional biomarkers that enhance clinical insights. The company's platform examines RNA biomarkers linked to responses to targeted therapeutics, allowing biotechnology firms to create clinical diagnostic assays for oncology, immunology, and neurodegenerative diseases. With a CAP-certified clinical RNA sequencing laboratory and a suite of molecular, informatic, and database tools, Cofactor supports its partners in conducting more efficient and successful clinical trials, ultimately facilitating the commercialization of innovative therapeutic solutions.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, founded in 2010. The company specializes in rational drug design, focusing on mechanistically novel kinase inhibitors aimed at addressing unmet medical needs in cancer and chronic inflammatory diseases. Its KINect technology platform is pivotal for identifying and developing new protein kinase drugs that target crucial enzymes involved in cancer growth, survival, and metastasis, as well as in modulating chronic inflammation. Unlike many competitors, Confluence Life Sciences explores novel binding sites on challenging kinase targets and previously un-targeted kinases. The company is driven by a team of experts with significant pharmaceutical experience, allowing it to pursue innovative strategies beyond traditional industry focus. To enhance its business potential, Confluence Life Sciences is also establishing scientific and business collaborations, fostering a pipeline strategy of discovery, development, and partnership. As of August 2017, it operates as a subsidiary of Aclaris Life Sciences, Inc.

GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic medications, particularly in therapeutic areas such as cardiovascular health, pain management, central nervous system disorders, oncology, and age-related conditions. Founded in 2013 and headquartered in Saint Louis, Missouri, GeneriCo also operates offices in Bengaluru, India; Italy; and South Korea. The company focuses on niche generic pharmaceuticals that larger competitors often overlook, particularly those that involve complex formulations and advanced drug delivery technologies. By targeting these neglected areas, GeneriCo aims to fill gaps in the market and provide valuable treatments for healthcare professionals, ultimately enhancing the quality of life for patients worldwide.

NeuroLutions Inc. is a company based in St. Louis, Missouri, that specializes in developing brain-computer interface (BCI) devices aimed at restoring functions for patients disabled by neurological injuries. Founded in 2007, the company focuses on creating non-invasive neurorehabilitation devices that assist stroke survivors in regaining lost arm function. Utilizing non-invasive electroencephalography (EEG) electrodes, NeuroLutions' technology captures brain activity without the need for implanted electrodes. This EEG data is wirelessly transmitted to a tablet, where it is analyzed to interpret the patient's intended muscle movements. The devices facilitate muscle re-education and help maintain or enhance the range of motion, offering a promising avenue for rehabilitation in individuals affected by neurological conditions.

CoverCress is a biotechnology company that focuses on research and development of renewable fuel and livestock feed. It specializes in producing an oilseed crop for food, bioenergy, and cattle feed. It specializes in the fields of agriculture, biotechnology, plants, genetics, cover crop, and precision agriculture. CoverCress was founded in 2013 by Jerry Steiner and Dr. Tim Ulmasov and is headquartered in St. Louis Missouri.

Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds from Euclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs.

Cardialen, Inc., a medical device company that develops a therapy system that detects and treats atrial fibrillation, rapid ventricular tachycardia, and ventricular fibrillation. It offers an implantable device to restore normal heart rhythm and may reduce the potential for high-energy defibrillation shocks. The company was incorporated in 2008 and is based in Minneapolis, Minnesota.

Developer of gene regulation technology designed to produce ribonucleic acid (RNA). The company's technology addresses some of the challenges to the mass production of exogenous RNAi-based products using a large scale fermentation process, enabling farmers to protect and improve their crops and cattle with the help of cost-efficient production of RNA.

SynerZ Medical, Inc. develops medical device for the treatment of obesity and type 2 diabetes. The company was incorporated in 2013 and is based in St. Louis, Missouri.

YourBevCo, LLC is a beverage device company focused on creating innovative consumer devices designed to eliminate problematic ingredients from beverages that may trigger allergic reactions or sensitivities. The company specializes in a portable, recyclable, single-use device specifically aimed at removing sulfites from wine. This technology addresses health concerns associated with sulfites, which can generate free radicals linked to cellular damage and increased disease risk. By enabling users to enjoy their drinks without compromising on appearance, aroma, or taste, YourBevCo aims to enhance the overall beverage experience while promoting safer consumption practices.

ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy treatments for metastatic solid tumor cancers. Founded in 2008 and based in Missouri, the company specializes in a proprietary drug product designed for use as an in situ autologous cancer vaccine. This product utilizes a carbohydrate polymer that is intratumorally injected following tumor ablation. By leveraging the tumor-associated neoantigens released during the ablation process, the treatment aims to induce a systemic anti-tumor immune response. ImmunoPhotonics has also formed a strategic partnership with Veterinary Cancer Therapeutics, LLC to further its research and development efforts in cancer therapy.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

Prostate Management Diagnostics creates tests and develops a fluid-based screening tool. It specializes in the fields of health diagnostics, medical, and healthcare. It was founded in 2014 and headquartered in San Francisco, California.

MedSocket of Missouri, Inc. specializes in health information technology solutions aimed at enhancing patient care efficiency and quality. Founded in 2012 and based in Columbia, Missouri, the company offers two patented products: 1-Click Decision Support (1-CDS) and 1-Search. Designed by clinicians for clinicians, these tools facilitate quick access to evidence-based information at the point of care, thereby improving healthcare decision-making. Both technologies have undergone successful piloting at the University of Missouri Health System, demonstrating their potential to reduce readmission rates, minimize transcription errors, and improve overall patient outcomes. MedSocket was established by Dr. Karl Kochendorfer, who recognized the need for rapid information retrieval in clinical settings, and further developed by Matt Botkin and Jayne Williams, who contributed business and information science expertise to the company’s mission.

Euclises Pharmaceuticals, Inc is developing novel pain and cancer medications that offer superior safety margins compared to existing drugs. The company is based on new inventions from Dr. John Talley, the most accomplished medicinal chemist in the world. Dr. Talley previously invented Celebrex and seven other approved drugs. New compounds from Euclises will offer both improved efficacy and safety relative to existing therapies. Euclises is located at the BioGenerator Accelerator Labs.

ImmunoPhotonics, Inc. is a biotechnology company focused on developing innovative immunotherapy treatments for metastatic solid tumor cancers. Founded in 2008 and based in Missouri, the company specializes in a proprietary drug product designed for use as an in situ autologous cancer vaccine. This product utilizes a carbohydrate polymer that is intratumorally injected following tumor ablation. By leveraging the tumor-associated neoantigens released during the ablation process, the treatment aims to induce a systemic anti-tumor immune response. ImmunoPhotonics has also formed a strategic partnership with Veterinary Cancer Therapeutics, LLC to further its research and development efforts in cancer therapy.

Edis Solutions offers an enterprise system designed for competitive drug research and forecasting. Their software tool, Confluence, enables clients to efficiently gather, filter, and present essential pharmaceutical intelligence. By automating processes that were previously manual, Edis Solutions enhances reliability in decision-making and strategic planning. The platform is tailored to streamline the collection and presentation of crucial data, allowing clients to focus on informed planning rather than time-consuming assembly.

Benson Hill is an agricultural technology company focused on crop improvement, particularly in soy protein innovation. By leveraging its proprietary CropOS™ platform, the company integrates machine learning, genomic data, and traditional breeding techniques to streamline the development of healthier and more sustainable food products. Benson Hill emphasizes unlocking the natural genetic diversity of plants to empower innovators in creating flavorful and nutritious ingredients. The company operates a Crop Accelerator for rapid prototyping and is developing a diverse seed portfolio that includes protein ingredients, aquaculture, specialty animal feed, and vegetable oils. Its revenue is generated from both proprietary and non-proprietary product categories, reflecting its commitment to advancing agricultural innovation.

Tansna Therapeutics, Inc. is a drug discovery and development company based in St. Louis, Missouri, established in 2010. The company specializes in creating and commercializing oral medications aimed at treating epilepsy and other central nervous system disorders. Its primary focus is on developing novel oral anticonvulsant agents designed to effectively reduce seizure frequency in patients with epilepsy. By offering innovative therapies, Tansna Therapeutics aims to enhance treatment options for healthcare providers and improve the quality of life for those affected by these debilitating conditions.

BacterioScan, Inc. is a medical device company based in St. Louis, Missouri, focused on diagnosing and treating infectious diseases. The company has developed the 216Dx UTI System, which detects bacteria indicative of urinary tract infections (UTIs) in clinical urine samples and helps identify suitable antibiotic treatments. Additionally, BacterioScan offers the 216R Antibiotic Susceptibility Testing System, designed to detect bacterial infections, assess antibiotic resistance, and provide clinicians with tailored antimicrobial resistance profiles. Its precision bench-top systems facilitate rapid detection and real-time quantification of microbial growth, significantly enhancing laboratory efficiency compared to traditional plating methods. This innovative approach not only aids clinicians in personalizing patient care but also supports researchers in accelerating the development of new antibiotics. BacterioScan's technology aims to improve the quality of antibiotic therapy and mitigate the risks associated with antibiotic resistance.

Graematter, Inc. specializes in regulatory intelligence solutions, offering a comprehensive platform that allows regulatory professionals to efficiently locate, analyze, and track essential regulatory information. The SOFIE Regulatory Intelligence System integrates data from various authoritative sources, including the Department of Health and Human Services, the Food and Drug Administration, and other regulatory bodies, facilitating monitoring of the regulatory landscape for aspects such as inspections, sanctions, and adverse events. The platform features tools such as Fast Search for broad queries, Advanced Search for detailed investigations, Regulatory Surveillance for new documents, and Trend Analysis to track key indicators. Additionally, Graematter provides research and regulatory consulting services to enhance clients' understanding and navigation of complex regulatory environments. Founded in 2012 and based in St. Louis, Missouri, the company has evolved its solutions since the initial concept was developed in 1999, continuously adapting to the growing volume and complexity of regulatory information.

GeneriCo, LLC is a pharmaceutical company that specializes in the development and marketing of generic medications, particularly in therapeutic areas such as cardiovascular health, pain management, central nervous system disorders, oncology, and age-related conditions. Founded in 2013 and headquartered in Saint Louis, Missouri, GeneriCo also operates offices in Bengaluru, India; Italy; and South Korea. The company focuses on niche generic pharmaceuticals that larger competitors often overlook, particularly those that involve complex formulations and advanced drug delivery technologies. By targeting these neglected areas, GeneriCo aims to fill gaps in the market and provide valuable treatments for healthcare professionals, ultimately enhancing the quality of life for patients worldwide.

Adarza BioSystems is an early-stage medical diagnostics company developing a rapid and label-free biological assay platform for measuring clinical and point-of-care (POC) samples. In addition to performing sophisticated clinical tests within minutes, this technology potentially allowing hundreds of tests to be run simultaneously on a single chip. It was founded in 2008 and headquartered in St Louis, Missouri.

Indalo Therapeutics is a preclinical-stage biotechnology company focused on developing innovative therapies for patients afflicted by fibrotic diseases. Founded on significant scientific advancements, the company leverages deep insights into the molecular mechanisms that drive abnormal scarring. By assembling a skilled team of pharmaceutical scientists and industry executives, Indalo aims to address critical unmet medical needs in the field of fibrosis. Its therapeutic approach seeks to not only halt but also potentially reverse the progression of fibrotic conditions, ultimately improving the quality of life for affected individuals.

Antegrin Therapeutics, LLC, is a drug discovery and development company focused on the development of novel therapies for fibrotic diseases. Our lead program aims to develop a treatment for idiopathic pulmonary fibrosis, a progressive, life-threatening condition that currently has no FDA-approved medication.

MediBeacon Inc. specializes in real-time kidney function monitoring solutions, focusing on advancing nephrology through innovative optical diagnostic technology. The company has developed the NIC-Kidney device, which enables monitoring of the glomerular filtration rate in preclinical settings, and the MediBeacon renal function system, which utilizes an optical skin sensor along with a proprietary agent that illuminates under light. This system allows for continuous real-time monitoring of kidney function, providing clinicians with critical data to enhance patient care. Additionally, MediBeacon's product pipeline includes a range of light-activated agents designed for physiological monitoring and surgical guidance. Founded in 2012 and headquartered in St. Louis, Missouri, MediBeacon aims to improve patient outcomes in intensive care units and operating rooms through its innovative approaches to organ function measurement and management.

Tansna Therapeutics, Inc. is a drug discovery and development company based in St. Louis, Missouri, established in 2010. The company specializes in creating and commercializing oral medications aimed at treating epilepsy and other central nervous system disorders. Its primary focus is on developing novel oral anticonvulsant agents designed to effectively reduce seizure frequency in patients with epilepsy. By offering innovative therapies, Tansna Therapeutics aims to enhance treatment options for healthcare providers and improve the quality of life for those affected by these debilitating conditions.

Benson Hill is an agricultural technology company focused on crop improvement, particularly in soy protein innovation. By leveraging its proprietary CropOS™ platform, the company integrates machine learning, genomic data, and traditional breeding techniques to streamline the development of healthier and more sustainable food products. Benson Hill emphasizes unlocking the natural genetic diversity of plants to empower innovators in creating flavorful and nutritious ingredients. The company operates a Crop Accelerator for rapid prototyping and is developing a diverse seed portfolio that includes protein ingredients, aquaculture, specialty animal feed, and vegetable oils. Its revenue is generated from both proprietary and non-proprietary product categories, reflecting its commitment to advancing agricultural innovation.

Confluence Life Sciences, Inc. is a drug discovery company based in Saint Louis, Missouri, founded in 2010. The company specializes in rational drug design, focusing on mechanistically novel kinase inhibitors aimed at addressing unmet medical needs in cancer and chronic inflammatory diseases. Its KINect technology platform is pivotal for identifying and developing new protein kinase drugs that target crucial enzymes involved in cancer growth, survival, and metastasis, as well as in modulating chronic inflammation. Unlike many competitors, Confluence Life Sciences explores novel binding sites on challenging kinase targets and previously un-targeted kinases. The company is driven by a team of experts with significant pharmaceutical experience, allowing it to pursue innovative strategies beyond traditional industry focus. To enhance its business potential, Confluence Life Sciences is also establishing scientific and business collaborations, fostering a pipeline strategy of discovery, development, and partnership. As of August 2017, it operates as a subsidiary of Aclaris Life Sciences, Inc.

As of January 8, 2019, Pulse Therapeutics, Inc. was acquired by Ichor Vascular, Inc. Pulse Therapeutics, Inc., a medical technology company, develops magnetically-enhanced diffusion (MED) system for the treatment of stroke, heart, and other diseases. Its MED system is used to harness magnet-based technology to dissolve blood clots faster than current modalities. The company also provides MED MicroBeads that are designed to convey physician-selected agents faster to the blood clot; intravenously administered after thrombolysis therapy is initiated; and mechanical adjunct to standard of care IV thrombolysis. In addition, it offers touch screen operated MED Workstation. Pulse Therapeutics, Inc. was incorporated in 2008 and is based in St. Louis, Missouri.

Apertus Pharmaceuticals is an Active Pharmaceutical Ingredient, or API, manufacturing company targeting dosage form manufacturing companies within the pharmaceutical industry. Apertus Pharmaceuticals provides controlled substance APIs, non controlled substance APIs, and intellectual property to the pharmaceutical market. In addition, Apertus Pharmaceuticals utilizes the philosophies of Green Chemistry as outlined by the FDA and will target higher purity standards than those set by the current standard setting authorities. Apertus is led by CEO Rick Ryan, Ph.D. and CSO David Gindelberger, Ph.D.

Kypha Inc. is an early-stage life sciences company focused on the discovery, development, and commercialization of in-vitro diagnostic biomarker tests targeting inflammation and autoimmune disorders. Based in St. Louis, Missouri, Kypha's flagship product, the COMP ACT System, is designed to enhance the monitoring and treatment of various health conditions, including lupus, stroke, traumatic brain injury, preeclampsia, infection, kidney disease, and transplant rejection. The system offers a rapid and accurate assessment of inflammation levels in the body, facilitating timely clinical interventions by healthcare professionals. Established in 2009, Kypha has successfully raised over $3 million in private capital and leveraged federal grants to advance its diagnostic offerings towards FDA clearance and commercial launch. The company operates with a small core team, supported by a network of scientific advisors and clinical collaborators.

Companion Pharma is an animal health product development company that will develop innovative new formulations of drugs for use under prescription in companion animals. Companion will specifically target companion animal disease indications that have a high unmet treatment need and will provide 'pet friendly' drugs that are proven to work safely in the target species, are formulated in a way to provide ease of administration and are available in doses that meet the needs of the highly variable weight profile of companion animal pets.

Developer of gene regulation technology designed to produce ribonucleic acid (RNA). The company's technology addresses some of the challenges to the mass production of exogenous RNAi-based products using a large scale fermentation process, enabling farmers to protect and improve their crops and cattle with the help of cost-efficient production of RNA.

ARTA Bioscience, Inc is developing new therapeutics for prostate cancer and inflammatory diseases. Current treatments for prostate cancer are insufficient and the disease is the second leading cause of cancer deaths among American men. ARTA's technology involves an entirely different approach to combating disease compared to traditional treatments. In addition to prostate cancer, the company's technologies may be used to target other important proteins in the nuclear receptor class. The company has established operations at the BioGenerator Accelerator Labs. ARTA's technology was developed by Dr. Marc Diamond at Washington University.

Array Bridge provides quality products and services for the pharmaceutical and biotechnology industry. Products include antibody arrays for biosimilar and antibody-drug conjugate (ADC) three-dimensional (3-D) conformational comparability analysis, ELISA kits for Host Cell Proteins including CHO and E. coli-derived biologics. Services include antibody production; Host Cell Protein and binding-based bioassay method qualification and validation; 1-D and 2-D gel analysis of process-related impurities; Western Blot analysis of HCPs; Residual DNA and Protein A analysis.

Mobius Therapeutics, LLC is a St. Louis-based company that specializes in developing sterile injectable pharmaceutical products for ophthalmic applications. Founded in 2006, the company focuses on delivering innovative solutions for ophthalmic surgery, with its flagship product, Mitosol, designed for the safe delivery of mitomycin, an antifibrotic agent, during glaucoma, refractive, and corneal surgeries. Mitosol includes a closed-system transfer device and sponge tray, facilitating the safe reconstitution and transfer of the medication. Additionally, Mobius Therapeutics offers Amphadase, a hyaluronidase injection. The company aims to enhance patient care by providing ophthalmologists with effective surgical solutions, and its products are available for purchase online.

Array Bridge provides quality products and services for the pharmaceutical and biotechnology industry. Products include antibody arrays for biosimilar and antibody-drug conjugate (ADC) three-dimensional (3-D) conformational comparability analysis, ELISA kits for Host Cell Proteins including CHO and E. coli-derived biologics. Services include antibody production; Host Cell Protein and binding-based bioassay method qualification and validation; 1-D and 2-D gel analysis of process-related impurities; Western Blot analysis of HCPs; Residual DNA and Protein A analysis.

Confluence Discovery Technologies is a contract research organization specializing in drug discovery, with a focus on the development of kinase inhibitors for cancer and inflammatory diseases. The company provides a range of technical services, including mechanistic enzymology, target validation, screening and assay development, as well as biomarker development and measurement. With decades of experience in developing clinical candidates, Confluence employs innovative strategies to identify effective kinase inhibitors that target key enzymes involved in cancer growth and chronic inflammation. Founded by former leaders from Pfizer's Inflammation Research Unit, Confluence operates from the BioGenerator Accelerator Labs, aiming to support healthcare providers in treating cancer and autoimmune conditions.

As of January 8, 2019, Pulse Therapeutics, Inc. was acquired by Ichor Vascular, Inc. Pulse Therapeutics, Inc., a medical technology company, develops magnetically-enhanced diffusion (MED) system for the treatment of stroke, heart, and other diseases. Its MED system is used to harness magnet-based technology to dissolve blood clots faster than current modalities. The company also provides MED MicroBeads that are designed to convey physician-selected agents faster to the blood clot; intravenously administered after thrombolysis therapy is initiated; and mechanical adjunct to standard of care IV thrombolysis. In addition, it offers touch screen operated MED Workstation. Pulse Therapeutics, Inc. was incorporated in 2008 and is based in St. Louis, Missouri.

PixelEXX Systems Inc. develops prototype imaging devices for diagnosing cancer. The products include nanoarrays that take images of molecular signals associated with cellular activity. PixelEXX Systems Inc. was founded in 2008 and is based in Saint Louis, Missouri.

APT Therapeutics is a biotechnology company based in St. Louis, Missouri, focused on developing innovative antiplatelet therapies. The company aims to transform human apyrase into a life-saving medicine through advanced techniques in protein engineering, protein informatics, and cheminformatics software. APT Therapeutics' therapies target critical medical conditions such as acute myocardial infarction, stroke, and complications arising from transplantation. By enhancing the effectiveness of these treatments, the company seeks to minimize damage to patients during heart attacks and improve their overall outcomes.